Ongoing 2b/3a inhibition In Myocardial infarction Evaluatio
- Conditions
- Acute myocardial infarctionCirculatory System
- Registration Number
- ISRCTN06195297
- Lead Sponsor
- Diagram B.V. (Netherlands)
- Brief Summary
2008 results in: http://www.ncbi.nlm.nih.gov/pubmed/18707985 2010 results in: http://www.ncbi.nlm.nih.gov/pubmed/20510211 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/22162050 2011 results in: http://www.ncbi.nlm.nih.gov/pubmed/21744314 2017 subgroup analysis in: http://www.ncbi.nlm.nih.gov/pubmed/28679686 2018 results in: http://www.ncbi.nlm.nih.gov/pubmed/30585388
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 950
1. Symptoms of acute myocardial infarction of more than 30 minutes
2. ST segment elevation of >1 mV in 2 adjacent ECG leads, with cumulative ST segment deviation of 6 mm or more
3. Ability to perform PCA within 6 hours after onset of symptoms
1. Patient with a contraindication to anticoagulation:
a. Present bleeding disorder including gastrointestinal bleeding, hematuria, or known presence of occult blood in the stool prior to randomisation
b. Systolic blood pressure persistently exceeding 200 mm Hg and/or diastolic blood pressure exceeding 110 mm Hg at time of enrolment
c. Recent (<6 mnd) Stroke or Transient Ischemic Attack
2. Patients with severe renal failure (hemodialysis)
3. Patient with recent (< 30 days) major surgery
Participation in another clinical study one year before enrolment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the effect of upfront pre-treatment with a high bolus dosage of Tirofiban on the extent of residual ST segment deviation 1 hour after Primary Coronary Angioplasty for acute myocardial infarction, compared to no pre-treatment (besides Aspirin, Heparin and 600 mg of Clopidogrel).
- Secondary Outcome Measures
Name Time Method